Dear Readers,
We are starting the second year of our journal in a new English version. We believe that we have managed to create a quarterly that combines the form of an educational platform helpful in the postgraduate education process and at the same time a place for presenting the results of scientific research. At the current stage of efforts to indexation of the journal in the scientific databases, it is very important to regularly publish subsequent issues. To achieve this, in addition to the inflow of new manuscripts, a timely review process was necessary. We have achieved this thanks to the invaluable help of the expert reviewers listed in Table 1, to whom we would like to thank.
Magdalena Durlik Joanna Gotlib Magdalena Jankowska Dorota Kamińska Sylwia Małgorzewicz Tomasz Stompór Monika Wieliczko Aleksandra Żurkowska |
The past year was full of important achievements in nephrology. It is worth mentioning at least the publication of groundbreaking evidence for the treatment of patients with chronic kidney disease on the nephroprotective potential of SGTL-2 inhibitors, both in patients with diabetic and non-diabetic kidney disease [1, 2]. This achievement was also reflected in our quarterly, where we published several papers on this issue last year [3, 4]. Review articles on the principles of using a low-protein diet and hypoxia-inducible factor-prolyl hydroxylase inhibitors, prolyl hydroxylase inhibitors, a new group of drugs used in the treatment of anemia also met with great interest [5, 6].
In this year’s first issue of the journal, which we are now giving you, we publish several interesting articles on the principles of communication with patients treated with peritoneal dialysis, the advantages of regular physical activity, the first part of the study on the history and physiological basis of bloodletting and an article on sudden cardiac death in early stages of renal replacement therapy.
Wishing you a pleasant reading, we leave you with the latest issue of the Renal Disease and Transplantation Forum.
Conflict of interest
None to declared.